Cargando…

Integrating Experimentation and Quantitative Modeling to Enhance Discovery of Beta Amyloid Lowering Therapeutics for Alzheimer’s Disease

Drug discovery can benefit from a proactive-knowledge-attainment philosophy which strategically integrates experimentation and pharmacokinetic/pharmacodynamic (PK/PD) modeling. Our programs for Alzheimer’s disease (AD) illustrate such an approach. Compounds that inhibit the generation of brain beta...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lu, Yasong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Research Foundation 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463859/ https://www.ncbi.nlm.nih.gov/pubmed/23060797 http://dx.doi.org/10.3389/fphar.2012.00177

Ejemplares similares

Precision Medicine in Alzheimer’s Disease: Investigating Comorbid Common Biological Substrates in the Rat Model of Amyloid Beta-Induced Toxicity
por: Morgese, Maria Grazia, et al.
Publicado: (2022)

The Protective Effects of PSM-04 Against Beta Amyloid-Induced Neurotoxicity in Primary Cortical Neurons and an Animal Model of Alzheimer’s Disease
por: Park, Hyunjun, et al.
Publicado: (2019)

Icariside II Effectively Reduces Spatial Learning and Memory Impairments in Alzheimer’s Disease Model Mice Targeting Beta-Amyloid Production
por: Yan, Lingli, et al.
Publicado: (2017)

Ursolic acid and rosmarinic acid ameliorate alterations in hippocampal neurogenesis and social memory induced by amyloid beta in mouse model of Alzheimer’s disease
por: Mirza, Fatima Javed, et al.
Publicado: (2022)

Curcumin Attenuates Beta-Amyloid-Induced Neuroinflammation via Activation of Peroxisome Proliferator-Activated Receptor-Gamma Function in a Rat Model of Alzheimer's Disease
por: Liu, Zun-Jing, et al.
Publicado: (2016)

β-Amyloid: the key peptide in the pathogenesis of Alzheimer’s disease
por: Sun, Xiaojuan, et al.
Publicado: (2015)

Exploring the Contribution of Estrogen to Amyloid-Beta Regulation: A Novel Multifactorial Computational Modeling Approach
por: Anastasio, Thomas J.
Publicado: (2013)

Doxycycline for Alzheimer’s Disease: Fighting β-Amyloid Oligomers and Neuroinflammation
por: Balducci, Claudia, et al.
Publicado: (2019)

Quantitative in vivo assessment of amyloid-beta phagocytic capacity in an Alzheimer’s disease mouse model
por: Lau, Shun-Fat, et al.
Publicado: (2021)

Editorial: Model organisms in experimental pharmacology and drug discovery 2022
por: Nainu, Firzan, et al.
Publicado: (2023)

MicroRNA-200a-3p Mediates Neuroprotection in Alzheimer-Related Deficits and Attenuates Amyloid-Beta Overproduction and Tau Hyperphosphorylation via Coregulating BACE1 and PRKACB
por: Wang, Linlin, et al.
Publicado: (2019)

β-Asarone Inhibits Amyloid-β by Promoting Autophagy in a Cell Model of Alzheimer's Disease
por: Wang, Nanbu, et al.
Publicado: (2020)

Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance
por: Marr, Robert A., et al.
Publicado: (2014)

Experimental Pharmacology in Transgenic Rodent Models of Alzheimer’s Disease
por: Cuello, A. Claudio, et al.
Publicado: (2019)

Targeting Synaptic Plasticity in Experimental Models of Alzheimer’s Disease
por: Mango, Dalila, et al.
Publicado: (2019)

Amyloid Beta in Aging and Alzheimer’s Disease
por: Sehar, Ujala, et al.
Publicado: (2022)

Derivatives of 9-phosphorylated acridine as butyrylcholinesterase inhibitors with antioxidant activity and the ability to inhibit β-amyloid self-aggregation: potential therapeutic agents for Alzheimer’s disease
por: Makhaeva, Galina F., et al.
Publicado: (2023)

Discovery of Quercetin and Its Analogs as Potent OXA-48 Beta-Lactamase Inhibitors
por: Zhang, Yuejuan, et al.
Publicado: (2022)

Changes in PGC‐1α/SIRT1 Signaling Impact on Mitochondrial Homeostasis in Amyloid-Beta Peptide Toxicity Model
por: Panes, Jessica D., et al.
Publicado: (2020)

Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy
por: Saito, Satoshi, et al.
Publicado: (2021)

Biotransformation of beta-endorphin and possible therapeutic implications
por: Asvadi, Naghmeh H., et al.
Publicado: (2014)

Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease
por: Xiang, Yang, et al.
Publicado: (2015)

Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer’s Disease
por: Menendez-Gonzalez, Manuel, et al.
Publicado: (2018)

Amyloid-beta Alzheimer targets — protein processing, lipid rafts, and amyloid-beta pores
por: Arbor, Sage C., et al.
Publicado: (2016)

Sleep and β-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments
por: Cordone, Susanna, et al.
Publicado: (2019)

The Neuroprotective Action of Amidated-Kyotorphin on Amyloid β Peptide-Induced Alzheimer’s Disease Pathophysiology
por: Belo, Rita F., et al.
Publicado: (2020)

Editorial: Insights in Experimental Pharmacology and Drug Discovery: 2021
por: Trostchansky, Andres, et al.
Publicado: (2022)

Editorial: Women in experimental pharmacology and drug discovery: 2021
por: Rižner, Tea Lanišnik, et al.
Publicado: (2022)

Editorial: Insights in experimental pharmacology and drug discovery: 2022
por: Latini, Alexandra, et al.
Publicado: (2023)

Soluble beta amyloid evokes alteration in brain norepinephrine levels: role of nitric oxide and interleukin-1
por: Morgese, Maria G., et al.
Publicado: (2015)

Naringin Chelates Excessive Iron and Prevents the Formation of Amyloid-Beta Plaques in the Hippocampus of Iron-Overloaded Mice
por: Jahanshahi, Mehrdad, et al.
Publicado: (2021)

The battle of Alzheimer’s Disease – the beginning of the future Unleashing the potential of academic discoveries
por: Lundkvist, Johan, et al.
Publicado: (2014)

Cannabinoid CB(2) Receptors Modulate Microglia Function and Amyloid Dynamics in a Mouse Model of Alzheimer’s Disease
por: Ruiz de Martín Esteban, Samuel, et al.
Publicado: (2022)

Editorial: Therapeutic and Diagnosis Target Discovery Based on Metabolomics
por: Liu, Linsheng
Publicado: (2022)

Editorial: Methods and application in experimental pharmacology and drug discovery: 2021
por: Polito, Letizia, et al.
Publicado: (2022)

Editorial: Spotlight on artificial intelligence in experimental pharmacology and drug discovery
por: Schöning, Verena, et al.
Publicado: (2023)

Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans
por: Lu, Yasong, et al.
Publicado: (2014)

A possible mechanism for the enhanced toxicity of beta-amyloid protofibrils in Alzheimer’s disease
por: Chen, Zu-Lin, et al.
Publicado: (2023)

Editorial on, “Amyloid-beta clearance in Alzheimer's disease”
por: Marr, Robert A.
Publicado: (2014)

Amyloid Beta and MicroRNAs in Alzheimer’s Disease
por: Amakiri, Nnana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s2sebunhtbog5ilm9k73gt9mcf